Sanofi is tight-lipped about the future of its underwhelming pact with Denali Therapeutics after the French pharma scrapped what appeared to be the final RIPK1 inhibitor from the deal. | Sanofi is ...
Analysis from continued follow-up of Phase 1/2 clinical trial data in Hunter syndrome (MPS II) reinforces potential for tividenofusp alfa ...
Denali Therapeutics (NASDAQ:DNLI) used an analyst call from the 2026 WORLD Symposium in San Diego to highlight new and ...
The discovery of a tumor in a patient who received REGENXBIO’s gene therapy for Hurler syndrome prompted the FDA to place a hold on that program along with the company’s Hunter syndrome program, which ...
Anchorage, Alaska — A climber was found dead on North America's tallest peak, Denali, on Monday, a day after a family member told rangers they hadn't heard from them in days, authorities said. The ...
Hunter syndrome (MPS II) presentations will include analysis from continued follow-up of Phase 1/2 data for tividenofusp alfa (DNL310), currently under FDA Priority ReviewPreliminary data from Phase 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results